Literature DB >> 22623771

B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.

Saikat Boliar1, Megan K Murphy, T Cameron Tran, Diane G Carnathan, Wendy S Armstrong, Guido Silvestri, Cynthia A Derdeyn.   

Abstract

Aberrant expression of regulatory receptors programmed death-1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) is linked with dysregulation and exhaustion of T lymphocytes during chronic human immunodeficiency virus type 1 (HIV-1) infection; however, less is known about whether a similar process impacts B-lymphocyte function during HIV-1 infection. We reasoned that disruption of the peripheral B cell compartment might be associated with decreased neutralizing antibody activity. Expression of markers that indicate dysregulation (BTLA and PD-1), immune activation (CD95), and proliferation (Ki-67) was evaluated in B cells from HIV-1-infected viremic and aviremic subjects and healthy subjects, in conjunction with immunoglobulin production and CD4 T cell count. Viral load and cross-clade neutralizing activity in plasma from viremic subjects were also assessed. Dysregulation of B lymphocytes was indicated by a marked disruption of peripheral B cell subsets, increased levels of PD-1 expression, and decreased levels of BTLA expression in viremic subjects compared to aviremic subjects and healthy controls. PD-1 and BTLA were correlated in a divergent fashion with immune activation, CD4 T cell count, and the total plasma IgG level, a functional correlate of B cell dysfunction. Within viremic subjects, the total IgG level correlated directly with cross-clade neutralizing activity in plasma. The findings demonstrate that even in chronically infected subjects in which B lymphocytes display multiple indications of dysfunction, antibodies that mediate cross-clade neutralization breadth continue to circulate in plasma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623771      PMCID: PMC3421653          DOI: 10.1128/JVI.00771-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.

Authors:  F P Kroon; J T van Dissel; J C de Jong; K Zwinderman; R van Furth
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

2.  Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.

Authors:  E Beirnaert; P Nyambi; B Willems; L Heyndrickx; R Colebunders; W Janssens; G van der Groen
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

3.  HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.

Authors:  E Michelle Long; Stephanie M J Rainwater; Ludo Lavreys; Kishorchandra Mandaliya; Julie Overbaugh
Journal:  AIDS Res Hum Retroviruses       Date:  2002-05-20       Impact factor: 2.205

4.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

5.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

6.  Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection.

Authors:  Angelo De Milito; Anna Nilsson; Kehmia Titanji; Rigmor Thorstensson; Elisabet Reizenstein; Mitsuo Narita; Sven Grutzmeier; Anders Sönnerborg; Francesca Chiodi
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

7.  Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.

Authors:  Jörn E Schmitz; Marcelo J Kuroda; Sampa Santra; Meredith A Simon; Michelle A Lifton; Wenyu Lin; Rajinder Khunkhun; Michael Piatak; Jeffrey D Lifson; Gudrun Grosschupff; Rebecca S Gelman; Paul Racz; Klara Tenner-Racz; Keith A Mansfield; Norman L Letvin; David C Montefiori; Keith A Reimann
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Authors:  Norihiko Watanabe; Maya Gavrieli; John R Sedy; Jianfei Yang; Francesca Fallarino; Susan K Loftin; Michelle A Hurchla; Natalie Zimmerman; Julia Sim; Xingxing Zang; Theresa L Murphy; John H Russell; James P Allison; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2003-06-08       Impact factor: 25.606

9.  Specific antibody production by blood B cells is retained in late stage drug-naïve HIV-infected Africans.

Authors:  Lydie Béniguel; Evelyne Bégaud; Fabrice Cognasse; Philippe Gabrié; Christophe D Mbolidi; Mary A Marovich; Céline Cazorla; Frédéric Lucht; Christian Genin; Olivier Garraud
Journal:  Clin Dev Immunol       Date:  2004-06

10.  Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.

Authors:  Susan Moir; Angela Malaspina; Oxana K Pickeral; Eileen T Donoghue; Joshua Vasquez; Natalie J Miller; Surekha R Krishnan; Marie A Planta; John F Turney; J Shawn Justement; Shyamasundaran Kottilil; Mark Dybul; JoAnn M Mican; Colin Kovacs; Tae-Wook Chun; Charles E Birse; Anthony S Fauci
Journal:  J Exp Med       Date:  2004-09-06       Impact factor: 14.307

View more
  24 in total

1.  Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Authors:  J Pablo Jaworski; James Kobie; Zachary Brower; Delphine C Malherbe; Gary Landucci; William F Sutton; Biwei Guo; Jason S Reed; Enrique J Leon; Flora Engelmann; Bo Zheng; Al Legasse; Byung Park; Mary Dickerson; Anne D Lewis; Lois M A Colgin; Michael Axthelm; Ilhem Messaoudi; Jonah B Sacha; Dennis R Burton; Donald N Forthal; Ann J Hessell; Nancy L Haigwood
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

2.  The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women.

Authors:  Nell S Lurain; Barbara A Hanson; Anna L Hotton; Kathleen M Weber; Mardge H Cohen; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-22       Impact factor: 2.205

3.  Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Authors:  Samantha Burton; Lori M Spicer; Tysheena P Charles; Sailaja Gangadhara; Pradeep B J Reddy; Tiffany M Styles; Vijayakumar Velu; Sudhir Pai Kasturi; Traci Legere; Eric Hunter; Bali Pulendran; Rama Amara; Peter Hraber; Cynthia A Derdeyn
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

Review 4.  Tumor necrosis factor superfamily in innate immunity and inflammation.

Authors:  John Šedý; Vasileios Bekiaris; Carl F Ware
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-12-18       Impact factor: 10.005

5.  A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.

Authors:  Sarah Welbourn; Srirupa Chakraborty; Jie E Yang; Anne S Gleinich; Sailaja Gangadhara; Salar Khan; Courtney Ferrebee; Bhrugu Yagnik; Samantha Burton; Tysheena Charles; S Abigail Smith; Danielle Williams; Rohini Mopuri; Amit A Upadhyay; Justin Thompson; Matt A Price; Shiyu Wang; Zhaohui Qin; Xiaoying Shen; LaTonya D Williams; Nathan Eisel; Tiffany Peters; Lu Zhang; William Kilembe; Etienne Karita; Georgia D Tomaras; Steven E Bosinger; Rama R Amara; Parastoo Azadi; Elizabeth R Wright; Sandrasegaram Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2022-05-03       Impact factor: 6.823

Review 6.  Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.

Authors:  Cynthia A Derdeyn; Penny L Moore; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

7.  Elevation of Tim-3 and PD-1 expression on T cells appears early in HIV infection, and differential Tim-3 and PD-1 expression patterns can be induced by common γ -chain cytokines.

Authors:  Zi-Ning Zhang; Ming-Lu Zhu; Yan-Hong Chen; Ya-Jing Fu; Tong-Wei Zhang; Yong-Jun Jiang; Zhen-Xing Chu; Hong Shang
Journal:  Biomed Res Int       Date:  2015-01-22       Impact factor: 3.411

8.  PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.

Authors:  Edward Seung; Timothy E Dudek; Todd M Allen; Gordon J Freeman; Andrew D Luster; Andrew M Tager
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

Review 9.  Molecular signatures of T-cell inhibition in HIV-1 infection.

Authors:  Marie Larsson; Esaki M Shankar; Karlhans F Che; Alireza Saeidi; Rada Ellegård; Muttiah Barathan; Vijayakumar Velu; Adeeba Kamarulzaman
Journal:  Retrovirology       Date:  2013-03-20       Impact factor: 4.602

Review 10.  Immune activation and collateral damage in AIDS pathogenesis.

Authors:  Frank Miedema; Mette D Hazenberg; Kiki Tesselaar; Debbie van Baarle; Rob J de Boer; José A M Borghans
Journal:  Front Immunol       Date:  2013-09-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.